Jeffrey Chodakewitz Sells 3,438 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 3,438 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $151.80, for a total value of $521,888.40. Following the completion of the sale, the chief marketing officer now owns 57,862 shares in the company, valued at $8,783,451.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Friday, November 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $144.71, for a total value of $779,986.90.
  • On Tuesday, October 31st, Jeffrey Chodakewitz sold 60,000 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $145.05, for a total value of $8,703,000.00.
  • On Monday, October 16th, Jeffrey Chodakewitz sold 1,718 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $155.19, for a total value of $266,616.42.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down $0.90 during trading hours on Wednesday, reaching $152.01. The company’s stock had a trading volume of 1,603,979 shares, compared to its average volume of 1,492,900. Vertex Pharmaceuticals Incorporated has a 12-month low of $74.87 and a 12-month high of $167.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. The firm has a market cap of $38,440.00, a P/E ratio of 194.88, a price-to-earnings-growth ratio of 1.90 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same quarter in the prior year, the business earned $0.16 EPS. The business’s revenue for the quarter was up 39.7% compared to the same quarter last year. analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Vertex Pharmaceuticals by 0.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after buying an additional 75 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,383 shares of the pharmaceutical company’s stock worth $823,000 after buying an additional 101 shares in the last quarter. Private Advisor Group LLC lifted its holdings in Vertex Pharmaceuticals by 2.4% during the 2nd quarter. Private Advisor Group LLC now owns 5,457 shares of the pharmaceutical company’s stock worth $702,000 after buying an additional 129 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares in the last quarter. Finally, Stephens Inc. AR lifted its holdings in Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Stephens Inc. AR now owns 13,315 shares of the pharmaceutical company’s stock worth $1,716,000 after buying an additional 143 shares in the last quarter. 93.09% of the stock is currently owned by hedge funds and other institutional investors.

VRTX has been the topic of several analyst reports. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Royal Bank of Canada upped their price objective on Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Cowen reiterated a “buy” rating and issued a $200.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, December 11th. Deutsche Bank assumed coverage on Vertex Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price target on the stock. Finally, Vetr lowered Vertex Pharmaceuticals to a “sell” rating in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $173.22.

COPYRIGHT VIOLATION WARNING: “Jeffrey Chodakewitz Sells 3,438 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/jeffrey-chodakewitz-sells-3438-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply